>VRTX – if SGP's Phase 3 is sufficient for a registration strategy in the second line, then why should VRTX have to run a greater burden since Prove 3 is already larger and more comprehensive…<
SGP’s phase-3 trial in the second line ('RESPOND-2') will not be sufficient for approval all by itself, IMO.
p.s. Thanks for the pointer on which webcasts to listen to.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”